FDA and OpenAI meeting to discuss AI in drug evaluation - Wired

The U.S. Food and Drug Administration is holding talks with OpenAI, the Microsoft ( NASDAQ: MSFT ) backed generative artificial intelligence startup, to discuss the agency’s use of AI, according to Wired citing sources.

The sources, who are close to the project, say a small.